Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, USA.
Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, USA.
Drug Discov Today. 2019 Oct;24(10):2033-2043. doi: 10.1016/j.drudis.2019.07.007. Epub 2019 Aug 2.
Recent research demonstrating that the glutamatergic modulator ketamine has rapid, robust, and sustained antidepressant effects has been a turning point in drug discovery for depression. The recent FDA approval of esketamine for adults with treatment-resistant major depressive disorder (MDD) has further underscored the relevance of this agent in spurring investigation into novel and mechanistically distinct agents for use in depression. Over the past two decades, ketamine research has ushered in a new wave of studies seeking to not only identify its mechanism of action but also to examine the antidepressant potential of novel or repurposed agents. This article reviews the approaches that have proven particularly fruitful for the field of neuropsychiatry.
最近的研究表明，谷氨酸调节剂氯胺酮具有快速、强大和持久的抗抑郁作用，这是抑郁症药物发现的一个转折点。最近 FDA 批准氯胺酮用于治疗难治性重度抑郁症（MDD）的成年人，进一步强调了该药物在推动对新型、机制不同的抗抑郁药物的研究中的相关性。在过去的二十年中，氯胺酮研究迎来了一波新的研究浪潮，不仅旨在确定其作用机制，还旨在研究新型或重新定位药物的抗抑郁潜力。本文综述了对神经精神病学领域特别有成效的方法。
